Document Detail


Von Willebrand factor-cleaving protease activity and proteolysis of von Willebrand factor in bone marrow transplant-associated thrombotic microangiopathy.
MedLine Citation:
PMID:  11920264     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: Thrombotic microangiopathy (TM) of the fulminant type occurring in patients following bone marrow transplant (BMT) has clinical manifestations that are similar to thrombotic thrombocytopenic purpura (TTP) and hemolytic uremic syndrome, but the outcome is generally fatal despite conventional therapy. Idiopathic acquired TTP has been associated with IgG inhibitors to the cleaving protease of von Willebrand factor (vWF) in plasma. In this study, we investigated the role of the vWF protease and vWF proteolysis in the pathogenesis of BMT-associated TM of the fulminant type. METHODS: vWF antigen level, vWF multimeric pattern, and vWF metalloprotease activity were investigated in the plasma samples of six consecutive patients with acute BMT-associated TM. Histologic and immunohistochemical studies were also performed on autopsy kidney specimens from four of the patients. All six patients had the fulminant type of the disorder with a fatal outcome and none of the patients responded to plasma infusion. RESULTS: The vWF-cleaving protease activity in plasma was normal in all patients. However, analysis of the vWF multimeric pattern showed a decrease of high molecular weight multimers. The decrease of large multimers may be caused by vWF-platelet binding as well as shear enhanced proteolysis of vWF. In the four patients who had an autopsy, a pattern of arteriolar thrombosis, distinct from that of TTP, was detected in the kidneys. CONCLUSION: These findings suggest that BMT-associated TM of the fulminant type is a heterogeneous process and distinct from TTP in pathogenesis. Analysis of vWF protease and vWF multimeric distribution are valuable tools in making the distinction between BMT-associated TM and TTP.
Authors:
S Arai; C Allan; M Streiff; G M Hutchins; G B Vogelsang; H M Tsai
Related Documents :
6184024 - Hetastarch as a prime for cardiopulmonary bypass.
16911684 - Clinical significance of measuring blood coagulation factor xiiia regularly and continu...
19551464 - Multiple myeloma presenting with acquired factor viii inhibitor.
17102654 - Life-threatening bleeding in a patient with a lupus inhibitor and probable acquired fac...
16569524 - Capsule endoscopy findings in patients with suspected crohn's disease and biochemical m...
11701254 - Clinical analysis of west syndrome associated with phenylketonuria.
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  The hematology journal : the official journal of the European Haematology Association / EHA     Volume:  2     ISSN:  1466-4860     ISO Abbreviation:  Hematol. J.     Publication Date:  2001  
Date Detail:
Created Date:  2002-03-28     Completed Date:  2002-06-27     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  100965523     Medline TA:  Hematol J     Country:  England    
Other Details:
Languages:  eng     Pagination:  292-9     Citation Subset:  IM    
Affiliation:
Johns Hopkins Oncology Center, Johns Hopkins Hospital, Baltimore, Maryland 21231-1000, USA. araisa@jhmi.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
ADAM Proteins
Adult
Bone Marrow Transplantation / adverse effects*
Diagnosis, Differential
Dimerization
Female
Hemolytic-Uremic Syndrome / diagnosis,  etiology*
Humans
Kidney / blood supply
Male
Metalloendopeptidases / metabolism*
Microcirculation
Middle Aged
Purpura, Thrombotic Thrombocytopenic / diagnosis,  etiology
Syndrome
Thrombosis
von Willebrand Factor / metabolism*
Grant Support
ID/Acronym/Agency:
R01 HL62131/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/von Willebrand Factor; EC 3.4.24.-/ADAM Proteins; EC 3.4.24.-/ADAMTS13 protein, human; EC 3.4.24.-/Metalloendopeptidases

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive l...
Next Document:  Variability in B-cell antigen expression: implications for the treatment of B-cell lymphomas and leu...